Assistant Professor of Oncology, Johns Hopkins University School of Medicine
Oncology
Dr. Danijela Jelovac, MD
|
|
Give Review
Danijela Jelovac works in the field of Oncology. She received awards:"CMS Meaningful Use Stage 1 Certification". Danijela Jelovac has written publications. She has 27 publications published with PubMed. The lastest publication is: 'Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.' Danijela Jelovac accepts Medicare payments and is registered with Medicare.gov.
Publications
- Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian Cancer.
- Treatment of HER2-positive breast Cancer.
- A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung Cancers.
- HER2-directed therapy for metastatic breast Cancer.
- Aromatase and breast Cancer.
- Mutation of a single allele of the Cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.
- Recent progress in the diagnosis and treatment of ovarian Cancer.
- PTEN promoter silencing and Cowden syndrome: the role of epigenetic regulation of KILLIN.
- PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human Breast epithelial cells.
- Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast Cancer xenografts to antiestrogens.
- Docetaxel followed by castration improves outcomes in LNCaP prostate Cancer-bearing severe combined immunodeficient mice.
- The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate Cancer cells.
- Model systems: mechanisms involved in the loss of sensitivity to letrozole.
- Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast Cancer model.
- Activation of mitogen-activated protein kinase in xenografts and Cells during prolonged treatment with aromatase inhibitor letrozole.
- The role of growth factor receptor pathways in human breast Cancer cells adapted to long-term estrogen deprivation.
- Therapeutic observations in MCF-7 aromatase xenografts.
- Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate Cancer model.
- Effects of exemestane and tamoxifen in a postmenopausal breast Cancer model.
- Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast Cancer.
- Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast Cancer model.
- The ceramide Analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts.
- The relationship between aromatase in primary Breast tumors and response to treatment with aromatase inhibitors in advanced disease.
- The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
- Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
- The effect of second-line antiestrogen therapy on Breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the in...
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Johns Hopkins University -
University of Belgrade Faculty of Medicine
Hospital
-
Johns Hopkins Bayview Medical Center -
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1053593582 | |
| NPPES Provider LastName | JELOVAC | |
| NPPES Provider FirstName | DANIJELA | |
| NPPES Provider ZIPCode | 212246821 | |
| NPPES Provider State | MD | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 141.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 14.0 | |
| Percent Opioid Claims | 9.93 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1053593582 |
| Last Name Of The Provider | JELOVAC |
| First Name Of The Provider | DANIJELA |
| View All |
Similar Doctors
|
|
Dr. Carole B. Miller, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hetty E. Carraway, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel A. Laheru, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Gabriel Ghiaur, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald B. Gartenhaus, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Arlene A. Forastiere, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ivan M. Borrello, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Michael Kraut, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Tanya M. Prowell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Diana H. Griffiths, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joshua E. Lubek, MD
This Doctor is OpenDoctor Recommended.
|